Aktien Sensor

Pro Medicus Ltd’s share price surged to record highs after securing two major contracts worth $170 million and $20 million, solidifying its position as a leader in the health technology sector.

AbbVie’s stock price plummets due to rising R&D costs and a reckless spending spree on acquisitions.

Fresenius Medical Care has partnered with a Mexican healthcare organization to expand its dialysis therapy services, including High-Volume Hemodiafiltration (HDF) treatment, in seven out of ten centers.

Novartis’ flagship medication Cosentyx has failed to meet its primary endpoint in a Phase III study, dealing a significant blow to the company’s revenue hopes and stock price.

Lonza Group AG’s stock price has experienced fluctuations, but has stabilized and remains strong due to the company’s expertise in the life sciences industry.

CVS Health Corp has emerged as a stable investment opportunity, driven by its limited exposure to market risks, strong performance in pharmacy and consumer wellness segments, and strategic partnerships.

AstraZeneca PLC has made significant progress with the approval of its Imfinzi asset in the European Union and potential US listing, boosting the company’s stock price and future prospects.

Humana Inc’s stock price has seen a moderate increase due to the company’s expanding healthcare services, including a new Medicaid plan in Virginia, despite some challenges with its subsidiary CenterWell.

Intuitive Surgical Inc’s stock price has increased significantly over the past year, driven by the approval of its advanced da Vinci 5 Surgical System in Europe.

Incyte Corporation has undergone a significant leadership change, sparking a re-evaluation of the company’s prospects and a moderate decline in its stock price.